Interdisciplinary cardiovascular and thoracic surgery · 2026
Association Between Pre-Transplant Psoas Sarcopenia and Perioperative Outcomes in Lung Transplant Recipients: A Single-Centre Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vaillant Garance, Zappella Nathalie, Kantor Elie, El Husseini Kinan, Saker Loukbi, Atchade Enora, Montravers Philippe, Hajouji Linda, Mal Hervé, Mordant Pierre, Khalil Antoine, Messika Jonathan, Bunel Vincent
Аннотация
OBJECTIVES: Lung transplantation (LTx) is the solid organ transplantation with the comparatively worst prognosis. Therefore, improving candidate selection and risk stratification for these patients has become a high-priority research focus. Incorporating objective markers of frailty such as sarcopenia in the pretransplant evaluation may help achieve this goal. We evaluated the association between CT-measured psoas muscle sarcopenia and early LTx outcomes.
METHODS: We performed a retrospective study including patients who underwent LTx from 2014 to 2018 at our institution with available chest and abdominal CT scans in the year prior to LTx. The psoas cross-sectional area was measured, and previously established sex-specific cutoffs were used to define sarcopenia. We compared sarcopenic and non-sarcopenic LTx recipients regarding 1-year mortality and perioperative outcomes.
RESULTS: A total of 140 patients were included, who received LTx primarily for interstitial lung disease (ILD) (n = 75, 53%) or chronic obstructive pulmonary disease (n = 54, 39%). Forty-six (33%) were sarcopenic. We found no association between psoas sarcopenia and 1-year all-cause mortality (multivariable P = .13) nor perioperative complications or FEV1 at 1 year post-LTx. Exploratory subgroup analysis revealed an association between psoas sarcopenia and 1-year all-cause mortality in patients with ILD (multivariable P = .042).
CONCLUSIONS: Pre-established sex-specific cutoffs for psoas sarcopenia did not reach statistical significance for 1-year mortality or perioperative outcomes in the overall cohort; given the limited statistical power, a clinically meaningful association cannot be excluded. An exploratory signal in ILD patients warrants further investigation. Future studies may benefit from disease-specific threshold validation and the integration of muscle strength and physical performance alongside muscle mass assessment.
METHODS: We performed a retrospective study including patients who underwent LTx from 2014 to 2018 at our institution with available chest and abdominal CT scans in the year prior to LTx. The psoas cross-sectional area was measured, and previously established sex-specific cutoffs were used to define sarcopenia. We compared sarcopenic and non-sarcopenic LTx recipients regarding 1-year mortality and perioperative outcomes.
RESULTS: A total of 140 patients were included, who received LTx primarily for interstitial lung disease (ILD) (n = 75, 53%) or chronic obstructive pulmonary disease (n = 54, 39%). Forty-six (33%) were sarcopenic. We found no association between psoas sarcopenia and 1-year all-cause mortality (multivariable P = .13) nor perioperative complications or FEV1 at 1 year post-LTx. Exploratory subgroup analysis revealed an association between psoas sarcopenia and 1-year all-cause mortality in patients with ILD (multivariable P = .042).
CONCLUSIONS: Pre-established sex-specific cutoffs for psoas sarcopenia did not reach statistical significance for 1-year mortality or perioperative outcomes in the overall cohort; given the limited statistical power, a clinically meaningful association cannot be excluded. An exploratory signal in ILD patients warrants further investigation. Future studies may benefit from disease-specific threshold validation and the integration of muscle strength and physical performance alongside muscle mass assessment.